New approaches to selectively target cancer-associated matrix metalloproteinase activity

Cancer and Metastasis Reviews

Volumn 33, Issue 4, 2014, Pages 1043-1057

  Tauro, Marilena ^a   McGuire, Jeremy ^a   Lynch, Conor C ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Activity based protein probes; Cancer progression and metastasis; Extracellular matrix; Matrix metalloproteinase; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NATURAL PRODUCT;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR IMAGING; NANOTECHNOLOGY; NONHUMAN; OVERALL SURVIVAL; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; CARCINOGENESIS; DRUG EFFECTS; GENETICS; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

CARCINOGENESIS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84914163554     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9530-4     Document Type: Article

References (111)

1. Overall, C. M., & Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nature Reviews Cancer, 2(9), 657–72. doi:10.1038/nrc884.
2. Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2(3), 161–74.
3. Nagase, H., & Woessner, J. F., Jr. (1999). Matrix metalloproteinases. Journal Biological Chemistry, 274(31), 21491–4.
4. Khokha, R., Murthy, A., & Weiss, A. (2013). Metalloproteinases and their natural inhibitors in inflammation and immunity. Nature Reviews Immunology, 13(9), 649–65. doi:10.1038/nri3499.
5. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., & Shafie, S. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284(5751), 67–8.
6. Devel, L., Czarny, B., Beau, F., Georgiadis, D., Stura, E., & Dive, V. (2010). Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1′ cavity. Biochimie, 92(11), 1501–8. doi:10.1016/j.biochi.2010.07.017.
7. Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science, 295(5564), 2387–92.
8. Fingleton, B. (2007). Matrix metalloproteinases as valid clinical targets. Current Pharmaceutical Design, 13(3), 333–46.
9. Lopez-Otin, C., & Overall, C. M. (2002). Protease degradomics: a new challenge for proteomics. Nature Reviews Molecular Cell Biology, 3(7), 509–19. doi:10.1038/nrm858.
10. Zucker, S., & Cao, J. (2009). Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: Ready for prime time? Cancer Biology and Therapy, 8(24), 2371–3.
11. Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27(31), 5287–97. doi:10.1200/JCO.2009.23.5556.
12. Rodriguez, D., Morrison, C. J., & Overall, C. M. (2010). Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochimica et Biophysica Acta, 1803(1), 39–54. doi:10.1016/j.bbamcr.2009.09.015.
13. Overall, C. M., & Blobel, C. P. (2007). In search of partners: Linking extracellular proteases to substrates. Nature Reviews Molecular Cell Biology, 8(3), 245–57. doi:10.1038/nrm2120.
14. Lopez-Otin, C., & Matrisian, L. M. (2007). Emerging roles of proteases in tumour suppression. Nature Reviews Cancer, 7(10), 800–8. doi:10.1038/nrc2228.
15. Gonzalo, P., Guadamillas, M. C., Hernandez-Riquer, M. V., Pollan, A., Grande-Garcia, A., Bartolome, R. A., et al. (2010). MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Developmental Cell, 18(1), 77–89. doi:10.1016/j.devcel.2009.11.012.
16. Correia, A. L., Mori, H., Chen, E. I., Schmitt, F. C., & Bissell, M. J. (2013). The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90beta. Genes and Development, 27(7), 805–17. doi:10.1101/gad.211383.112.
17. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., & Cravatt, B. F. (2004). Activity-based probes for the proteomic profiling of metalloproteases. Proceedings of the National Academy of Sciences of the United States of America, 101(27), 10000–5. doi:10.1073/pnas.0402784101.
18. Browner, M. F., Smith, W. W., & Castelhano, A. L. (1995). Matrilysin-inhibitor complexes: Common themes among metalloproteases. Biochemistry, 34(20), 6602–10.
19. Puerta, D. T., Lewis, J. A., & Cohen, S. M. (2004). New beginnings for matrix metalloproteinase inhibitors: Identification of high-affinity zinc-binding groups. Journal of the American Chemical Society, 126(27), 8388–9. doi:10.1021/ja0485513.
20. Quantin, B., Murphy, G., & Breathnach, R. (1989). Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry, 28(13), 5327–34.
21. Chandler, S., Cossins, J., Lury, J., & Wells, G. (1996). Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochemical and Biophysical Research Communications, 228(2), 421–9. doi:10.1006/bbrc.1996.1677.
22. Tochowicz, A., Maskos, K., Huber, R., Oltenfreiter, R., Dive, V., Yiotakis, A., et al. (2007). Crystal structures of MMP-9 complexes with five inhibitors: Contribution of the flexible Arg424 side-chain to selectivity. Journal of Molecular Biology, 371(4), 989–1006. doi:10.1016/j.jmb.2007.05.068.
23. Tao, P., Fisher, J. F., Mobashery, S., & Schlegel, H. B. (2009). DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2. Organic Letters, 11(12), 2559–62. doi:10.1021/ol9008393.
24. Kleifeld, O., Kotra, L. P., Gervasi, D. C., Brown, S., Bernardo, M. M., Fridman, R., et al. (2001). X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme. Journal of Biological Chemistry, 276(20), 17125–31.
25. Weinspach, D., Seubert, B., Schaten, S., Honert, K., Sebens, S., Altevogt, P., et al. (2014). Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: Promotion of dissemination, colonization, and metastatic growth. Clinical and Experimental Metastasis, 31(1), 87–100. doi:10.1007/s10585-013-9613-6.
26. Bonfil, R. D., Sabbota, A., Nabha, S., Bernardo, M. M., Dong, Z., Meng, H., et al. (2006). Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. International Journal of Cancer, 118(11), 2721–6.
27. Gooyit, M., Song, W., Mahasenan, K. V., Lichtenwalter, K., Suckow, M. A., Schroeder, V. A., et al. (2013). O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood–brain barrier. Journal of Medicinal Chemistry, 56(20), 8139–50. doi:10.1021/jm401217d.
28. Puerta, D. T., Griffin, M. O., Lewis, J. A., Romero-Perez, D., Garcia, R., Villarreal, F. J., et al. (2006). Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: Potency, toxicity, and reactivity. Journal of Biological Inorganic Chemistry: JBIC: a Publication of the Society of Biological Inorganic Chemistry, 11(2), 131–8. doi:10.1007/s00775-005-0053-x.
29. Rubino, M. T., Agamennone, M., Campestre, C., Campiglia, P., Cremasco, V., Faccio, R., et al. (2011). Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem, 6(7), 1258–68. doi:10.1002/cmdc.201000540.
30. Thiolloy, S., Edwards, J. R., Fingleton, B., Rifkin, D. B., Matrisian, L. M., & Lynch, C. C. (2012). An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. PloS One, 7(1), e29862. doi:10.1371/journal.pone.0029862PONE-D-11-14696.
31. Tauro, M., Laghezza, A., Loiodice, F., Agamennone, M., Campestre, C., Tortorella, P. (2013). Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorganic & Medicinal Chemistry, 21(21), 6456–6465.
32. Kolb, H. C., & Sharpless, K. B. (2003). The growing impact of click chemistry on drug discovery. Drug Discovery Today, 8(24), 1128–37.
33. Lewis, W. G., Green, L. G., Grynszpan, F., Radic, Z., Carlier, P. R., Taylor, P., et al. (2002). Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angewandte Chemie, 41(6), 1053–7.
34. Hu, M., Li, J., & Yao, S. Q. (2008). In situ “click” assembly of small molecule matrix metalloprotease inhibitors containing zinc-chelating groups. Organic Letters, 10(24), 5529–31. doi:10.1021/ol802286g.
35. Scherer, R. L., McIntyre, J. O., & Matrisian, L. M. (2008). Imaging matrix metalloproteinases in cancer. Cancer and Metastasis Reviews, 27(4), 679–90. doi:10.1007/s10555-008-9152-9.
36. Howat, S., Park, B., Oh, I. S., Jin, Y. W., Lee, E. K., & Loake, G. J. (2014). Paclitaxel: Biosynthesis, production and future prospects. New Biotechnology, 31(3), 242–5. doi:10.1016/j.nbt.2014.02.010.
37. Payne, J. B., & Golub, L. M. (2011). Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacological Research: The Official Journal of the Italian Pharmacological Society, 63(2), 121–9. doi:10.1016/j.phrs.2010.10.006.
38. Fingleton, B. (2003). CMT-3. CollaGenex. Current Opinion in Investigational Drugs, 4(12), 1460–7.
39. Furlow, B. (2006). COL-3 benefits patients with AIDS-related Kaposi’s sarcoma. The Lancet Oncology, 7(5), 368.
40. Zhang, C., & Kim, S. K. (2012). Antimetastasis effect of anthraquinones from marine fungus, Microsporum sp. Advances in Food and Nutrition Research, 65, 415–21. doi:10.1016/B978-0-12-416003-3.00027-5.
41. Miyata, Y., Sato, T., Yano, M., & Ito, A. (2004). Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin. Molecular Cancer Therapeutics, 3(7), 839–47.
42. Rooprai, H. K., Kandanearatchi, A., Maidment, S. L., Christidou, M., Trillo-Pazos, G., Dexter, D. T., et al. (2001). Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathology and Applied Neurobiology, 27(1), 29–39.
43. Kawabata, K., Murakami, A., & Ohigashi, H. (2006). Citrus auraptene targets translation of MMP-7 (matrilysin) via ERK1/2-dependent and mTOR-independent mechanism. FEBS Letters, 580(22), 5288–94. doi:10.1016/j.febslet.2006.08.072.
44. Minagawa, A., Otani, Y., Kubota, T., Wada, N., Furukawa, T., Kumai, K., et al. (2001). The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Japanese Journal of Cancer Research: Gann, 92(12), 1322–8.
45. Shao, Z. M., Wu, J., Shen, Z. Z., & Barsky, S. H. (1998). Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Research, 18(3A), 1435–9.
46. Kousidou, O. C., Mitropoulou, T. N., Roussidis, A. E., Kletsas, D., Theocharis, A. D., & Karamanos, N. K. (2005). Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. International Journal of Oncology, 26(4), 1101–9.
47. Agarwal, C., Tyagi, A., Kaur, M., & Agarwal, R. (2007). Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis, 28(7), 1463–70. doi:10.1093/carcin/bgm042.
48. Agarwal, R., Agarwal, C., Ichikawa, H., Singh, R. P., & Aggarwal, B. B. (2006). Anticancer potential of silymarin: from bench to bed side. Anticancer Research, 26(6B), 4457–98.
49. Dell’Aica, I., Caniato, R., Biggin, S., & Garbisa, S. (2007). Matrix proteases, green tea, and St. John’s wort: biomedical research catches up with folk medicine. Clinica Chimica Acta; International Journal of Clinical Chemistry, 381(1), 69–77. doi:10.1016/j.cca.2007.02.022.
50. Yamakawa, S., Asai, T., Uchida, T., Matsukawa, M., Akizawa, T., & Oku, N. (2004). (−)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Letters, 210(1), 47–55. doi:10.1016/j.canlet.2004.03.008.
51. Cao, Y., Fu, Z. D., Wang, F., Liu, H. Y., & Han, R. (2005). Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. Journal of Asian Natural Products Research, 7(3), 205–13. doi:10.1080/10286020410001690190.
52. Tang, Z., Liu, X. Y., & Zou, P. (2007). Resveratrol inhibits the secretion of vascular endothelial growth factor and subsequent proliferation in human leukemia U937 cells. Journal of Huazhong University of Science and Technology Medical sciences =Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban =Huazhong keji daxue xuebao Yixue Yingdewen ban, 27(5), 508–12. doi:10.1007/s11596-007-0508-0.
53. Woo, J. H., Lim, J. H., Kim, Y. H., Suh, S. I., Min, D. S., Chang, J. S., et al. (2004). Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene, 23(10), 1845–53. doi:10.1038/sj.onc.1207307.
54. Vayalil, P. K., Mittal, A., & Katiyar, S. K. (2004). Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF kappa B. Carcinogenesis, 25(6), 987–95. doi:10.1093/carcin/bgh095.
55. Bodet, C., Chandad, F., & Grenier, D. (2007). Inhibition of host extracellular matrix destructive enzyme production and activity by a high-molecular-weight cranberry fraction. Journal of Periodontal Research, 42(2), 159–68. doi:10.1111/j.1600-0765.2006.00929.x.
56. Banerji, A., Chakrabarti, J., Mitra, A., & Chatterjee, A. (2004). Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Letters, 211(2), 235–42. doi:10.1016/j.canlet.2004.02.007.
57. Lin, L. I., Ke, Y. F., Ko, Y. C., & Lin, J. K. (1998). Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology (Williston Park), 55(4), 349–53.
58. Chen, H. W., Yu, S. L., Chen, J. J., Li, H. N., Lin, Y. C., Yao, P. L., et al. (2004). Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Molecular Pharmacology, 65(1), 99–110. doi:10.1124/mol.65.1.99.
59. Chen, H., Yan, X., Lin, J., Wang, F., & Xu, W. (2007). Depolymerized products of lambda-carrageenan as a potent angiogenesis inhibitor. Journal of Agricultural and Food Chemistry, 55(17), 6910–7. doi:10.1021/jf070183+.
60. Kim, J. A., Ahn, B. N., Kong, C. S., Park, S. H., Park, B. J., & Kim, S. K. (2012). Antiphotoaging effect of chitooligosaccharides on human dermal fibroblasts. Photodermatology, Photoimmunology & Photomedicine, 28(6), 299–306. doi:10.1111/phpp.12004.
61. Mannello, F. (2006). Natural bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon? Recent Patents on Anti-Cancer Drug Discovery, 1(1), 91–103.
62. Dredge, K. (2004). AE-941 (AEterna). Current Opinion in Investigational Drugs, 5(6), 668–77.
63. Tsao, R. (2010). Chemistry and biochemistry of dietary polyphenols. Nutrients, 2(12), 1231–46. doi:10.3390/nu2121231.
64. Babu, P. V., & Liu, D. (2008). Green tea catechins and cardiovascular health: an update. Current Medicinal Chemistry, 15(18), 1840–50.
65. Annabi, B., Lachambre, M. P., Bousquet-Gagnon, N., Page, M., Gingras, D., & Beliveau, R. (2002). Green tea polyphenol (−)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochimica et Biophysica Acta, 1542(1–3), 209–20.
66. Demeule, M., Brossard, M., Page, M., Gingras, D., & Beliveau, R. (2000). Matrix metalloproteinase inhibition by green tea catechins. Biochimica et Biophysica Acta, 1478(1), 51–60.
67. Fujita, M., Nakao, Y., Matsunaga, S., Seiki, M., Itoh, Y., Yamashita, J., et al. (2003). Ageladine A: an antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai. Journal of the American Chemical Society, 125(51), 15700–1. doi:10.1021/ja038025w.
68. Shengule, S. R., Loa-Kum-Cheung, W. L., Parish, C. R., Blairvacq, M., Meijer, L., Nakao, Y., et al. (2011). A one-pot synthesis and biological activity of ageladine A and analogues. Journal of Medicinal Chemistry, 54(7), 2492–503. doi:10.1021/jm200039m.
69. Falardeau, P., Champagne, P., Poyet, P., Hariton, C., & Dupont, E. (2001). Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Seminars in Oncology, 28(6), 620–5.
70. Lu, C., Lee, J. J., Komaki, R., Herbst, R. S., Feng, L., Evans, W. K., et al. (2010). Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. Journal of the National Cancer Institute, 102(12), 859–65. doi:10.1093/jnci/djq179.
71. Loprinzi, C. L., Levitt, R., Barton, D. L., Sloan, J. A., Atherton, P. J., Smith, D. J., et al. (2005). Evaluation of shark cartilage in patients with advanced cancer: a north central cancer treatment group trial. Cancer, 104(1), 176–82. doi:10.1002/cncr.21107.
72. Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautes-Fridman, C., Zitvogel, L., et al. (2014). Trial watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology, 3(1), e27048. doi:10.4161/onci.27048.
73. Acharya, U. H., & Jeter, J. M. (2013). Use of ipilimumab in the treatment of melanoma. Clinical Pharmacology: Advances and Applications, 5(Suppl 1), 21–7. doi:10.2147/CPAA.S45884.
74. Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2012). Bevacizumab: Overview of the literature. Expert Review of Anticancer Therapy, 12(5), 567–80. doi:10.1586/era.12.13.
75. Devy, L., Huang, L., Naa, L., Yanamandra, N., Pieters, H., Frans, N., et al. (2009). Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Research, 69(4), 1517–26. doi:10.1158/0008-5472.CAN-08-3255.
76. Naito, S., Takahashi, T., Onoda, J., Yamauchi, A., Kawai, T., Kishino, J., et al. (2012). Development of a neutralizing antibody specific for the active form of matrix metalloproteinase-13. Biochemistry, 51(44), 8877–84. doi:10.1021/bi301228d.
77. Shiryaev, S. A., Remacle, A. G., Golubkov, V. S., Ingvarsen, S., Porse, A., Behrendt, N., et al. (2013). A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP. Oncogenesis, 2, e80. doi:10.1038/oncsis.2013.44.
78. Fingleton, B., Powell, W. C., Crawford, H. C., Couchman, J. R., & Matrisian, L. M. (2007). A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo. Hybridoma (Larchmt), 26(1), 22–7. doi:10.1089/hyb.2006.028.
79. Lolmede, K., Campana, L., Vezzoli, M., Bosurgi, L., Tonlorenzi, R., Clementi, E., et al. (2009). Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. Journal of Leukocyte Biology, 85(5), 779–87. doi:10.1189/jlb.0908579.
80. Sela-Passwell, N., Kikkeri, R., Dym, O., Rozenberg, H., Margalit, R., Arad-Yellin, R., et al. (2012). Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nature Medicine, 18(1), 143–7. doi:10.1038/nm.2582.
81. Pei, D., Kang, T., & Qi, H. (2000). Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. The Journal of Biological Chemistry, 275(43), 33988–97. doi:10.1074/jbc.M006493200.
82. Sato, H., Okada, Y., & Seiki, M. (1997). Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thrombosis and Haemostasis, 78(1), 497–500.
83. Itoh, Y., & Seiki, M. (2006). MT1-MMP: a potent modifier of pericellular microenvironment. Journal of Cellular Physiology, 206(1), 1–8. doi:10.1002/jcp.20431.
84. Ota, I., Li, X. Y., Hu, Y., & Weiss, S. J. (2009). Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proceedings of the National Academy of Sciences of the United States of America, 106(48), 20318–23. doi:10.1073/pnas.0910962106.
85. Deu, E., Verdoes, M., & Bogyo, M. (2012). New approaches for dissecting protease functions to improve probe development and drug discovery. Nature Structural & Molecular Biology, 19(1), 9–16. doi:10.1038/nsmb.2203.
86. Olson, E. S., Jiang, T., Aguilera, T. A., Nguyen, Q. T., Ellies, L. G., Scadeng, M., et al. (2010). Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proceedings of the National Academy of Sciences of the United States of America, 107(9), 4311–6. doi:10.1073/pnas.0910283107.
87. Akers, W. J., Xu, B., Lee, H., Sudlow, G. P., Fields, G. B., Achilefu, S., et al. (2012). Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe. Bioconjugate Chemistry, 23(3), 656–63. doi:10.1021/bc300027y.
88. Turk, B. E., Huang, L. L., Piro, E. T., & Cantley, L. C. (2001). Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnology, 19(7), 661–7. doi:10.1038/90273.
89. Scherer, R. L., VanSaun, M. N., McIntyre, J. O., & Matrisian, L. M. (2008). Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Molecular Imaging, 7(3), 118–31.
90. Zhang, H. (2004). Pyro-Gly-Pro-Leu-Gly-Leu-Ala-Arg-Lys (BHQ3). Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD).
91. Fudala R, Rich R, Mukerjee A, Ranjan AP, Vishwanatha JK, Kurdowska AK, et al. (2012). Fluorescence detection of MMP-9.II. Ratiometric FRET-based sensing with dually labeled specific peptide. Current Pharmaceutical Biotechnology.
92. Lee, S., Xie, J., & Chen, X. (2010). Peptides and peptide hormones for molecular imaging and disease diagnosis. Chemical Reviews, 110(5), 3087–111. doi:10.1021/cr900361p.
93. Meyer, B. S., & Rademann, J. (2012). Extra- and intracellular imaging of human matrix metalloprotease 11 (hMMP-11) with a cell-penetrating FRET substrate. Journal of Biological Chemistry, 287(45), 37857–67. doi:10.1074/jbc.M112.371500.
94. Jabaiah, A., & Daugherty, P. S. (2011). Directed evolution of protease beacons that enable sensitive detection of endogenous MT1-MMP activity in tumor cell lines. Chemistry & Biology, 18(3), 392–401. doi:10.1016/j.chembiol.2010.12.017.
95. Zhu, L., Ma, Y., Kiesewetter, D. O., Wang, Y., Lang, L., Lee, S., et al. (2013). Rational design of matrix metalloproteinase-13 activatable probes for enhanced specificity. ACS Chemical Biology. doi:10.1021/cb400698s.
96. Chien, M. P., Carlini, A. S., Hu, D., Barback, C. V., Rush, A. M., Hall, D. J., et al. (2013). Enzyme-directed assembly of nanoparticles in tumors monitored by in vivo whole animal imaging and ex vivo super-resolution fluorescence imaging. Journal of the American Chemical Society. doi:10.1021/ja408182p.
97. Remacle, A. G., Shiryaev, S. A., Golubkov, V. S., Freskos, J. N., Brown, M. A., Karwa, A. S., et al. (2013). Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells. Journal of Biological Chemistry, 288(28), 20568–80. doi:10.1074/jbc.M113.471508.
98. Yu, S. S., Lau, C. M., Thomas, S. N., Jerome, W. G., Maron, D. J., Dickerson, J. H., et al. (2012). Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. International Journal of Nanomedicine, 7, 799–813. doi:10.2147/IJN.S28531.
99. Thorek, D. L., Ogirala, A., Beattie, B. J., & Grimm, J. (2013). Quantitative imaging of disease signatures through radioactive decay signal conversion. Nature Medicine, 19(10), 1345–50. doi:10.1038/nm.3323.
100. Kim, Y. P., Daniel, W. L., Xia, Z., Xie, H., Mirkin, C. A., & Rao, J. (2010). Bioluminescent nanosensors for protease detection based upon gold nanoparticle-luciferase conjugates. Chemical communications (Cambridge), 46(1), 76–8. doi:10.1039/b915612g.
101. Samuelson, L. E., Scherer, R. L., Matrisian, L. M., McIntyre, J. O., & Bornhop, D. J. (2013). Synthesis and in vitro efficacy of MMP9-activated NanoDendrons. Molecular Pharmaceutics, 10(8), 3164–74. doi:10.1021/mp4002206.
102. Shi, N. Q., Gao, W., Xiang, B., & Qi, X. R. (2012). Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. International Journal of Nanomedicine, 7, 1613–21. doi:10.2147/IJN.S30104.
103. Li, R., Wu, W., Liu, Q., Wu, P., Xie, L., Zhu, Z., et al. (2013). Intelligently targeted drug delivery and enhanced antitumor effect by gelatinase-responsive nanoparticles. PloS One, 8(7), e69643. doi:10.1371/journal.pone.0069643.
104. Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007). Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute, 99(19), 1441–54. doi:10.1093/jnci/djm135.
105. Danhier, F., Feron, O., & Preat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society, 148(2), 135–46. doi:10.1016/j.jconrel.2010.08.027.
106. Burris, H. A., 3rd, Tibbitts, J., Holden, S. N., Sliwkowski, M. X., & Lewis Phillips, G. D. (2011). Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clinical Breast Cancer, 11(5), 275–82. doi:10.1016/j.clbc.2011.03.018.
107. Gu, G., Xia, H., Hu, Q., Liu, Z., Jiang, M., Kang, T., et al. (2013). PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials, 34(1), 196–208. doi:10.1016/j.biomaterials.2012.09.044.
108. Kondo, M., Asai, T., Katanasaka, Y., Sadzuka, Y., Tsukada, H., Ogino, K., et al. (2004). Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. International Journal of Cancer, 108(2), 301–6. doi:10.1002/ijc.11526.
109. Van Valckenborgh, E., Mincher, D., Di Salvo, A., Van Riet, I., Young, L., Van Camp, B., et al. (2005). Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia, 19(9), 1628–33. doi:10.1038/sj.leu.2403866.
110. Ansari, C., Tikhomirov, G. A., Hong, S. H., Falconer, R. A., Loadman, P. M., Gill, J. H., et al. (2014). Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small, 10(3), 566–75. doi:10.1002/smll.201301456.
111. Morell, M., Nguyen Duc, T., Willis, A. L., Syed, S., Lee, J., Deu, E., et al. (2013). Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity. Journal of the American Chemical Society, 135(24), 9139–48. doi:10.1021/ja403523p.